SEC Form 4 · accession 0001232524-16-000362
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seamus Mulligan
Director
Period of report
Aug 25, 2016
Accepted (ET)
Aug 26, 2016 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Aug 25, 2016 | S | 3,565 | $126.651 | D | 1,072,411 | D | |
| Ordinary SharesF3 | Aug 25, 2016 | S | 9,500 | $127.7028 | D | 1,062,911 | D | |
| Ordinary SharesF4 | Aug 25, 2016 | S | 10,283 | $128.9693 | D | 1,052,628 | D | |
| Ordinary SharesF5 | Aug 25, 2016 | S | 4,620 | $129.4174 | D | 1,048,008 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $126.23 to $127.22. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $127.28 to $128.27. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $128.30 to $129.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $129.30 to $129.93. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.